# United Therapeutics

率先创造可移植的3D打印人体肺脏，以治愈终末期肺病。

Source: https://cn.bioecon.ru/companies/united-therapeutics/
Updated: 2026-06-24

- 国家: United States
- 代码: UTHR

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 2025年总营收约为$32亿。 | https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/press-releases/2026/4q25-factsheet.pdf |
| 产能 | 位于弗吉尼亚州的临床规模DPF设施目标产能为每年最多125个器官。 | https://corporateresponsibility.unither.com/~/media/Files/U/Unither-Corp/corporate-responsibility/unitedtherapeutics-corporateresponsibility-2025-lr.pdf, https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/press-releases/2024/uthr-4q24-10k.pdf, https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/press-releases/2026/uthr-10-k-2025.pdf |
| 产能 | 位于明尼苏达州斯图尔特维尔（Stewartville）的Starzl异种移植生产设施，容量为150只动物。 | https://www.postbulletin.com/business/stewartvilles-xenotransplant-pig-facility-is-ready-for-animals |
| 生产基地 | 位于弗吉尼亚州、明尼苏达州和德克萨斯州的指定无病原体（DPF）设施。 | https://corporateresponsibility.unither.com/~/media/Files/U/Unither-Corp/corporate-responsibility/unitedtherapeutics-corporateresponsibility-2025-lr.pdf, https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/press-releases/2024/uthr-4q24-10k.pdf, https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/press-releases/2026/uthr-10-k-2025.pdf |
| 生产基地 | 位于新罕布什尔州曼彻斯特的Organ Manufacturing Group。 | https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/press-releases/2024/uthr-4q24-10k.pdf, https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/press-releases/2026/uthr-10-k-2025.pdf, https://pipeline.unither.com/ |
| 生产基地 | 位于北卡罗来纳州三角研究园的再生医学实验室。 | https://corporateresponsibility.unither.com/~/media/Files/U/Unither-Corp/corporate-responsibility/unitedtherapeutics-corporateresponsibility-2025-lr.pdf, https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/investor-homepage/unitedtherapeutics-corporateresponsibility-2024-lr.pdf, https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/press-releases/2026/uthr-10-k-2025.pdf |
| 生产基地 | 位于马里兰州银泉市和佛罗里达州杰克逊维尔的EVLP设施。 | https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/press-releases/2026/uthr-10-k-2025.pdf |
| 员工人数 | 超过1,400名员工（根据2025年报告/数据）。 | https://corporateresponsibility.unither.com/~/media/Files/U/Unither-Corp/corporate-responsibility/unitedtherapeutics-corporateresponsibility-2025-lr.pdf, https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/press-releases/2026/4q25-factsheet.pdf |
| 营收 | 2025年总营收约为$32亿。 | https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/press-releases/2026/4q25-factsheet.pdf |
| 监管批准 | 获 FDA 批准的疗法包括 Tyvaso DPI、Nebulized Tyvaso、Remodulin、Orenitram、Unituxin 和 Adcirca。 | https://ir.unither.com/, https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/events-and-presentations/uthr-10q-q2-2026.pdf, https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/press-releases/2026/uthr-10-k-2025.pdf |
| 监管批准 | 首个获 FDA 批准上市的无细胞 EVLP 技术（配备 Steen Solution 的 XPS 系统）。 | https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/investor-homepage/unitedtherapeutics-corporateresponsibility-2024-lr.pdf, https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/press-releases/2026/uthr-10-k-2025.pdf |

独立来源: corporateresponsibility.unither.com, ir.unither.com, pipeline.unither.com, postbulletin.com

## 技术

- [器官与组织生物打印](https://cn.bioecon.ru/technology/organ-tissue-bioprinting/)